TW202227433A - 中環或大環之經苄基取代的雜環衍生物及相關用途 - Google Patents

中環或大環之經苄基取代的雜環衍生物及相關用途 Download PDF

Info

Publication number
TW202227433A
TW202227433A TW110132882A TW110132882A TW202227433A TW 202227433 A TW202227433 A TW 202227433A TW 110132882 A TW110132882 A TW 110132882A TW 110132882 A TW110132882 A TW 110132882A TW 202227433 A TW202227433 A TW 202227433A
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
alkenyl
present disclosure
halogen
Prior art date
Application number
TW110132882A
Other languages
English (en)
Chinese (zh)
Inventor
布魯斯 樂夫克
高登 薩斯提
卡爾 吉伯森
馬克 皮克沃
馬修 史班迪
邁爾斯 康格里夫
保羅 哈姆瑞斯
Original Assignee
英商歐瑞夏治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商歐瑞夏治療公司 filed Critical 英商歐瑞夏治療公司
Publication of TW202227433A publication Critical patent/TW202227433A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW110132882A 2020-09-03 2021-09-03 中環或大環之經苄基取代的雜環衍生物及相關用途 TW202227433A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063074220P 2020-09-03 2020-09-03
US63/074,220 2020-09-03

Publications (1)

Publication Number Publication Date
TW202227433A true TW202227433A (zh) 2022-07-16

Family

ID=78078371

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110132882A TW202227433A (zh) 2020-09-03 2021-09-03 中環或大環之經苄基取代的雜環衍生物及相關用途

Country Status (6)

Country Link
US (1) US20230331720A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208465A1 (cg-RX-API-DMAC7.html)
JP (1) JP7811578B2 (cg-RX-API-DMAC7.html)
CN (1) CN116635393A (cg-RX-API-DMAC7.html)
TW (1) TW202227433A (cg-RX-API-DMAC7.html)
WO (1) WO2022051583A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
JP7833486B2 (ja) * 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
WO2023167925A1 (en) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
US20260116891A1 (en) * 2022-04-22 2026-04-30 Teijin Pharma Limited Oxazepin Derivative
CN114716319B (zh) * 2022-04-28 2024-03-26 浙江工业大学 一种联芳氧基烯酸酯类化合物的合成方法
EP4600242A1 (en) * 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
UY40937A (es) * 2023-10-20 2025-04-30 Teijin Pharma Ltd Cristal de derivado de oxazepina o cristal de solvato del mismo
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US10428023B2 (en) * 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
PE20211700A1 (es) * 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법

Also Published As

Publication number Publication date
WO2022051583A1 (en) 2022-03-10
EP4208465A1 (en) 2023-07-12
JP2023540350A (ja) 2023-09-22
CN116635393A (zh) 2023-08-22
JP7811578B2 (ja) 2026-02-05
US20230331720A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
US12503475B2 (en) Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
US20230331720A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
TWI881008B (zh) 嗒基-噻唑甲醯胺化合物
WO2022207935A1 (en) 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
TW202003466A (zh) 人類整合素α4β7拮抗劑
KR20190005838A (ko) 이중 lsd1/hdac 억제제로서 사이클로프로필-아마이드 화합물
AU2023228830A1 (en) Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
CN119156375A (zh) 双环杂环衍生物和相关用途
TW202319043A (zh) 3,4-亞甲二氧甲基苯丙胺及相關致幻劑及其用途
CN106458976A (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
US20070254958A1 (en) Phenyl Carboxamide Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
CN114641466B (zh) 磺酰脲衍生物及其用途
CN114761383A (zh) 磺酰胺衍生物及其用途
CN110072859A (zh) 作为RORγ调节剂的化合物
CN111902401B (zh) 受体抑制剂、包含其的药物组合物及其用途
EA052303B1 (ru) Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения
WO2024099404A1 (zh) 一种含氮螺环类化合物、药物组合物以及其用途
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用
HK1263406A1 (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors
HK1263406B (en) Cyclopropyl-amide compounds as dual lsd1/hdac inhibitors